Curetis N.V. (the “Company” and together with its subsidiaries “Curetis“), a developer of next-level molecular diagnostic solutions, today published the invitation to its Annual General Shareholders’ Meeting (“AGM”) 2018.
Curetis will hold its AGM on June 21, 2018, at Steigenberger Hotel, Stationsplein Zuid – West 951, 1117 CE Schiphol – Oost/Amsterdam, the Netherlands. The meeting is scheduled to commence at 01:00 pm CEST; local registration starts at 12:30 pm CEST.
In addition, Curetis will be offering electronic pre-voting from Saturday, May 25, 2018, at 08:00 am CEST to June 14, 2018, at 05:30 pm CEST at www.abnamro.com/evoting.
A copy of the convening notice for the AGM, including a description of the formalities to participate in the AGM, is available at http://www.curetis.com/en/investors/share-information/annual-general-meeting.html.
Primary resolutions on the agenda of the AGM relate to the implementation of the new Dutch Corporate Governance Code within the Company and the nominations and proposals for re-appointment of Curetis N.V. Managing Directors Oliver Schacht, Ph.D. and Dr. Achim Plum for another three-year term, respectively, as well as the nomination and proposal for appointment of Christopher Bernard, President & CEO of the Company’s U.S. subsidiary Curetis USA Inc. as new Managing Director of Curetis N.V. for a term of three years. Moreover, resolutions on the agenda address the re-election of the Supervisory Board members Dr. Rudy Dekeyser for another one-year term and Dr. Werner Schaefer for another two-year term. Additional items on the agenda include the designation of the Management Board as the company body authorized to issue new shares or grant rights to subscribe for shares in relation to strategic capital raising(s) and to limit or exclude pre-emption rights on these shares.